Based on the Monopar Therapeutics Inc stock forecast from 3 analysts, the average analyst target price for Monopar Therapeutics Inc is USD 43.17 over the next 12 months. Monopar Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Monopar Therapeutics Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Monopar Therapeutics Inc’s stock price was USD 38.36. Monopar Therapeutics Inc’s stock price has changed by +32.64% over the past week, +28.94% over the past month and +916.16% over the last year.
No recent analyst target price found for Monopar Therapeutics Inc
No recent average analyst rating found for Monopar Therapeutics Inc
Company Overview Monopar Therapeutics Inc
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC. Read Less
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging...Read More
Frequently Asked Questions About Monopar Therapeutics Inc (MNPR) Stock
Based on ratings from 3 analysts Monopar Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on MNPR's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for MNPR is USD 43.17 over the next 12 months. The maximum analyst target price is USD 76 while the minimum anlayst target price is USD 9.
Unfortunately we do not have enough data on MNPR's stock to indicate if its overvalued.
The last closing price of MNPR's stock was USD 38.36.
The most recent market capitalization for MNPR is USD 0.21B.
Based on targets from 3 analysts, the average taret price for MNPR is projected at USD 43.17 over the next 12 months.
This means that MNPR's stock price may go up by +12.53% over the next 12 months.
We can't find any ETFs which contains Monopar Therapeutics Inc's stock.
As per our most recent records Monopar Therapeutics Inc has 9 Employees.
Monopar Therapeutics Inc's registered address is 1000 Skokie Boulevard, Wilmette, IL, United States, 60091.
You can get more information about it from Monopar Therapeutics Inc's website at https://www.monopartx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Monopar Therapeutics Inc (MNPR) Stock
Based on ratings from 3 analysts Monopar Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 6 buy, sell and hold ratings.
Unfortunately we do not have enough data on MNPR's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for MNPR is USD 43.17 over the next 12 months. The maximum analyst target price is USD 76 while the minimum anlayst target price is USD 9.
Unfortunately we do not have enough data on MNPR's stock to indicate if its overvalued.
The last closing price of MNPR's stock was USD 38.36.
The most recent market capitalization for MNPR is USD 0.21B.
Based on targets from 3 analysts, the average taret price for MNPR is projected at USD 43.17 over the next 12 months.
This means that MNPR's stock price may go up by +12.53% over the next 12 months.
We can't find any ETFs which contains Monopar Therapeutics Inc's stock.
As per our most recent records Monopar Therapeutics Inc has 9 Employees.
Monopar Therapeutics Inc's registered address is 1000 Skokie Boulevard, Wilmette, IL, United States, 60091.
You can get more information about it from Monopar Therapeutics Inc's website at https://www.monopartx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MNPR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
